Recent updates on Truvada lawsuits indicate ongoing litigation against Gilead as of February 2024. Plaintiffs are pursuing legal action not only concerning Truvada but also other drugs containing tenofovir disoproxil fumarate (TDF), alleging toxicity to bones and kidneys.
Despite the absence of court-approved settlements or jury verdicts thus far, the litigation progresses, with the scheduling of bellwether trials in California state and federal courts. Numerous cases are consolidated in California, with thousands of plaintiffs involved across multiple states.
In January 2024, federal consolidated Truvada HIV lawsuits in California remain pending, with some claims dismissed but others preserved by the overseeing federal judge. Meanwhile, the first federal trial is set for April 2024.
In November 2023, Gilead reached a preliminary settlement of $246.75 million in a price-fixing class action, addressing allegations of conspiracy to delay generic versions of their HIV drugs. A final approval hearing for this settlement is anticipated in January 2024.
September 2023 saw arguments in California appeals court regarding Gilead’s appeal of the denial of a motion for summary judgment in state-consolidated lawsuits. The motion alleged Gilead withheld a safer HIV drug to maximize profits.
Throughout 2023, developments included the commencement of summary jury trials, filing of new lawsuits by plaintiffs, and judicial actions such as the rejection of Gilead’s expert witnesses. As of December 2022, Gilead faced lawsuits from over 26,000 plaintiffs across several states.
While Gilead initially sought dismissal of California state cases, the Superior Court of California allowed plaintiffs’ claims to proceed in February 2019. Bellwether trials in California state court have been stayed pending a decision by the California First District Court of Appeal, while the first California federal court bellwether is scheduled for January 2024.
